



R**NR**

Supplementary Figure S13. T0-T1 values (after one month of nivolumab) between $PD-1^+$ Tregs and $HELIOS^+$ Tregs in Responder and Not Responder patients.

(A-B) Responder patients (R): $PD-1^+$ Tregs (N=30) median at T0= 69.85 and T1= 63.35, with 12 positive differences and 18 negative differences; $p= 0.2536$; $HELIOS^+$ Tregs (N=26) median at T0= 58.6 and T1= 53.95, 9 positive differences and 17 negative differences; $p= 0.0694$.

(C-D) Not Responder patients (NR): $PD-1^+$ Tregs (N=23) median T0= 38.7 and T1= 38.8, with 8 positive differences and 15 negative differences; $p= 0.369$; $HELIOS^+$ Tregs (N=19) median at T0= 31.1 and T1= 32.4, with 10 positive differences and 9 negative differences; $p= 0.650$. Statistical significance assessed by Wilcoxon matched-pairs signed rank test ($p<0.05$).